zipalertinib
·Code: CLN-081, TAS6417
zipalertinib: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | Phase 3 |
FDA Decisions
FDA_MeetingCompanies plan to submit for U.S. regulatory approval in the second half of 2025 pending discussions with the FDA.(CGEM)
Frequently asked questions
Who is developing zipalertinib?
zipalertinib is being developed by Cullinan Therapeutics, Inc..
What is zipalertinib's latest FDA decision?
The most recent tracked FDA decision for zipalertinib is FDA_Meeting for Companies plan to submit for U.S. regulatory approval in the second half of 2025 pending discussions with the FDA..
Get deeper analysis on zipalertinib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis